Short-term efficacy and safety of a lower dose of polyethylene glycol recombinant human growth hormone in children with growth hormone deficiency: A randomized, dose-comparison study

• Main Authors: Zhouhong Jiang (Author), Xuefeng Chen (Author), Guanping Dong (Author), Yin Lou (Author), Jianping Zhang (Author), Xinran Cheng (Author), Jiayan Pan (Author), Wei Liao (Author), Jinzhun Wu (Author), Xiaodong Huang (Author), Xianjiang Jin (Author), Deyun Liu (Author), Ting Zeng (Author), Shunye Zhu (Author), Qin Dong (Author), Xiaoming Luo (Author), Dan Lan (Author), Lizhi Cao (Author), Xingxing Zhang (Author), Jing Liu (Author), Mingjuan Dai (Author), Manyan Zhang (Author), Li Liu (Author), Junhua Dong (Author), Dongmei Zhao (Author), Shaoqing Ni (Author), Junfen Fu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Polyethylene glycol recombinant human growth hormone (PEG-rhGH, Jintrolong®) is the first long-acting rhGH preparation that is approved to treat children with growth hormone deficiency (GHD) in China. Clinical experience with dose selections of PEG-rhGH is scarce. The present study compar...